Lehmann S, Roche S, Allory Y, Barthelaix A, Beaudeux J-L, Berger F, Betsou F, Borg J, Dupuy A, Garin J, Quillard M, Lizard G, Peoc'h K, Riviere M, Ducoroy P
CHRU de Montpellier, Laboratoire de biochimie, Hôpital Saint Eloi, Montpellier, France.
Ann Biol Clin (Paris). 2009 Nov-Dec;67(6):629-39. doi: 10.1684/abc.2009.0374.
Research of new diagnosis or prognosis biomarkers is a major challenge for the management of patients with complex pathologies like cancer. Clinical proteomics is one of the recent approaches to identify these biomarkers in biological fluids. Over the last five years, many problems related to the variability and the quality control of these analyses have been observed. This was notably related to the different preanalytical status of each sample. A strong need for standardization of the critical preanalytical phases (collection, transport, processing, storage...) has been therefore recognized. With this goal in mind, working groups of the "Institut national du cancer" (INCa) and the "Société française de biologie clinique" (SFBC) proposed here preanalytical proteomics guidelines for the most common biological fluids: plasma, serum, urine and cerebrospinal fluid. To goal is to provide the basis for the harmonization of the procedures in clinical laboratories and biobanks to allow an optimal use of biological collections.
对于癌症等复杂病症患者的管理而言，新型诊断或预后生物标志物的研究是一项重大挑战。临床蛋白质组学是近年来在生物体液中识别这些生物标志物的方法之一。在过去五年中，人们观察到了许多与这些分析的变异性和质量控制相关的问题。这尤其与每个样本不同的分析前状态有关。因此，人们已经认识到迫切需要对关键的分析前阶段（采集、运输、处理、储存等）进行标准化。出于这一目标，法国国家癌症研究所（INCa）和法国临床生物学学会（SFBC）的工作组在此提出了针对最常见生物体液（血浆、血清、尿液和脑脊液）的分析前蛋白质组学指南。目标是为临床实验室和生物样本库中程序的协调统一提供基础，以便能够最佳地利用生物样本。
